Skip to main content
Ships fully reconstituted · no mixing, no powder, no bacteriostatic water
All peptides
AOD 9604
Energy

AOD 9604

Ships fully reconstituted · no mixing, no powder, no bacteriostatic water

Pure Fat Burning Peptide

A growth hormone fragment engineered specifically for targeted fat metabolism.

Choose your supply

Physician-reviewed · charged only after your prescription is approved
Free shipping over $350 · compounded in a U.S. pharmacy
Secure checkout · 256-bit encryption

Frequently paired with

What it supports

  • Targeted fat reduction without hormonal effects
  • No impact on blood sugar or IGF-1 levels
  • Supports sustainable weight management
  • Promotes lipolysis in adipose tissue
  • Does not affect appetite or muscle mass

The details

Administration
Subcutaneous injection
Format
3mg/mL, 5mL vial
Typical dosing
250-500mcg daily
Best for
Targeted fat reduction
Pairs well with
MOTS-C, CJC-1295/Ipamorelin
AOD 9604 mimics the fat-reducing action of growth hormone without affecting blood sugar or IGF-1 levels. It stimulates lipolysis and inhibits lipogenesis, targeting fat metabolism directly.

How it works

Signal

AOD-9604 is given as a subcutaneous injection, typically in the morning, on a provider-determined schedule.

Cellular response

AOD-9604 mimics the fat-reducing action of growth hormone without affecting blood sugar or IGF-1. It stimulates lipolysis and inhibits lipogenesis, targeting fat metabolism directly while sparing lean muscle.

Outcome

Over the following weeks most people notice subtle metabolic shifts and reduced bloating first (weeks 1–2), then more noticeable body-composition change around the midsection (weeks 2–4), then visible fat loss with muscle preserved (weeks 4–8), with the best results from week 8 onward — diet and exercise still do the heavy lifting.

Research highlights

FDA granted GRAS status for oral form

Studies show significant abdominal fat reduction

No impact on insulin sensitivity or IGF-1

Well-tolerated in clinical trials

Research summaries are provided for educational context and are not a promise of results. Talk with your provider about what to expect.

Sources & references

  • Fat reduction without growth effects

    Heffernan MA et al. Obes Res. 2001;9(12):813–819.

    View source
  • Human clinical trial

    Stier H et al. J Endocrinol Metab. 2004.

    View source
  • GRAS safety assessment

    Stier H et al. Regul Toxicol Pharmacol. 2015;72(2):358–364.

    View source

Common questions

Important safety information

AOD 9604 is available by prescription only and is dispensed after a licensed provider reviews your medical screening and determines it is appropriate for you. Compounded medications are prepared by a licensed U.S. pharmacy and are not FDA-approved products. Tell your provider about your full medical history and any medications you take.

  • Generally well tolerated
  • Possible injection site reactions
  • Should not be used during pregnancy
  • Requires licensed provider supervision